Loading clinical trials...
Loading clinical trials...
Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Conditions
Interventions
Duvelisib
Ibrutinib
Locations
1
United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Start Date
July 31, 2020
Primary Completion Date
January 22, 2021
Completion Date
January 22, 2021
Last Updated
March 9, 2022
NCT07030400
NCT06043011
NCT06528301
NCT03342144
NCT05168930
NCT04758975
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions